Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies
Open Access
- 16 December 2013
- journal article
- Published by Springer Science and Business Media LLC in Thrombosis Journal
- Vol. 11 (1), 25
- https://doi.org/10.1186/1477-9560-11-25
Abstract
The worldwide EINSTEIN DVT and EINSTEIN PE studies randomized 8282 patients with acute symptomatic deep-vein thrombosis (DVT) and/or pulmonary embolism (PE) and, for the first time in trials in this setting, included patients in China. This analysis evaluates the results of these studies in this subgroup of patients. A total of 439 Chinese patients who had acute symptomatic DVT (n=211), or PE with or without DVT (n=228), were randomized to receive rivaroxaban (15 mg twice daily for 21 days, followed by 20 mg once daily) or standard therapy of enoxaparin overlapping with and followed by an adjusted-dose vitamin K antagonist, for 3, 6, or 12 months. The primary efficacy outcome was symptomatic recurrent venous thromboembolism. The principal safety outcome was major or non-major clinically relevant bleeding. The primary efficacy outcome occurred in seven (3.2%) of the 220 patients in the rivaroxaban group and in seven (3.2%) of the 219 patients in the standard-therapy group (hazard ratio, 1.04; 95% confidence interval 0.36–3.0; p=0.94). The principal safety outcome occurred in 13 (5.9%) patients in the rivaroxaban group and in 20 (9.2%) patients in the standard-therapy group (hazard ratio, 0.63; 95% confidence interval 0.31–1.26; p=0.19). Major bleeding was observed in no patients in the rivaroxaban group and in five (2.3%) patients in the standard-therapy group. In fragile patients (defined as age >75 years, creatinine clearance <50 mL/min, and/or body weight ≤50 kg), the principal safety outcome occurred in four (8.9%) of the 45 patients who received rivaroxaban compared with seven (15.2%) of the 46 patients who received standard therapy. In Chinese patients with acute symptomatic DVT and/or PE, rivaroxaban was as efficacious as enoxaparin followed by vitamin K antagonist therapy, with a similar safety profile. The relative efficacy and safety of rivaroxaban compared with enoxaparin/vitamin K antagonist were consistent with that found in the rest of the world. EINSTEIN PE, ClinicalTrials.gov NCT00439777; EINSTEIN DVT, ClinicalTrials.gov NCT00440193Keywords
This publication has 18 references indexed in Scilit:
- Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studiesThrombosis Journal, 2013
- Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolismThrombosis Journal, 2013
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismThe New England Journal of Medicine, 2012
- Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2012
- Incidence of Deep Vein Thrombosis in Hospitalized Chinese Medical Patients and the Impact of DVT ProphylaxisThrombosis, 2011
- Rivaroxaban: A New Oral Factor Xa InhibitorArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban – an oral, direct factor Xa inhibitor – in elderly Chinese subjectsThrombosis and Haemostasis, 2010
- Incidence of deep vein thrombosis in hospitalized Chinese medical patients is similar to that in western populationsThrombosis Research, 2006
- Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate‐intensity anticoagulation?British Journal of Clinical Pharmacology, 2005
- ANTICOAGULANT DRUGS IN THE TREATMENT OF PULMONARY EMBOLISM: A CONTROLLED TRIALThe Lancet, 1960